PMV Pharma prices offering of up to $50.8 million in shares and warrants
PMV Pharma agreed on August 31, 2026 to sell 22,055,000 shares and pre-funded warrants for 19,900,000 shares, each sold with a warrant, at a combined price of $1.21 per share, with warrants for 41,955,000 shares in total. The company estimates net proceeds of about $47.0 million and expects the offering to close on September 2, 2026. The warrants' exercise price can reset after an FDA decision accepting the rezatapopt New Drug Application, which could increase the number of shares issuable and add dilution for existing shareholders.
Key points
- Offering includes 22,055,000 shares and pre-funded warrants for 19,900,000 shares, plus accompanying warrants for 41,955,000 shares, at a combined price of $1.21
- Gross proceeds expected to be about $50.8 million; estimated net proceeds about $47.0 million; closing expected September 2, 2026
- Warrants have a $1.21 initial exercise price and a five-year term; exercise price resets to the greater of 33% of the initial price or a VWAP-based level after the FDA NDA acceptance announcement for rezatapopt
- Company believes proceeds plus existing cash will fund operations and capital expenditures into the first quarter of 2028, excluding any underwriters' option exercise
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.